Mark Khachaturian, PhD
CEO
Wellvii
Dr. Khachaturian has been the CEO of Wellvii since September 2022 (Palm Beach Gardens, FL) where he leads the development and commercialization of novel consumer and remote patient monitoring vital sign measurement platforms. Dr. Khachaturian joined Wellvii in October 2016 as the CTO of Wellvii where he developed technology focusing on finger-based blood pressure, pre-diabetic (e.g. vascular stiffness) measurements, and glucose sensors which are no-touch or light touch. This device is accompanied by Android/iOS apps and HIPAA/GDPR compliant healthcare cloud IoT platform with EMR connectivity. This platform will improve the safety, reduce the cost, and increasing the accessibility of global wellness and chronic care monitoring in the home and ambulatory settings. Dr. Khachaturian is on the Advisory Board of Bond since January 2022 where he supports the development, manufacturing and procurement of hardware and software for security monitoring. Dr. Khachaturian to the board of directors of ApoQlar USA where he guides the development and certification of augmented reality hardware to transform medical images, clinical workflows and medical education into a 3D mixed reality environment. Dr. Khachaturian was previously the VP of R&D at ABT Molecular Imaging (Knoxville, TN) where he lead the development of a compact automated radiopharmaceutical production system for F-18 and C-11 based radio-pharmaceuticals. Prior to ABT, Dr. Khachaturian was the Lead System Designer at GE Healthcare (Waukesha, WI), where he lead of the design and manufacture of the Signa® PET/MRI system and lead the design of the Discovery MR750w, a wide bore 3 Tesla imaging system. Dr. Khachaturian received his PhD in Nuclear Science and Engineering from Massachusetts Institute of Technology (Cambridge, MA) with a focus on medical physics and medical imaging. He received a Bachelor of Science in Nuclear Engineering and Engineering Physics from the University of Michigan (Ann Arbor). Dr. Khachaturian is the inventor on more than 60 patents.